Do analysts rate BDRX or KTTA?

Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 576.28%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher valuation & earnings, BDRX or KTTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is BDRX or KTTA more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Pasithea Therapeutics N/A -57.44% -53.61%

Do analysts recommend BDRX or GDTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BDRX or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A CytoMed Therapeutics $250K 42.11 -$3.10M N/A N/A

Is BDRX or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A CytoMed Therapeutics N/A N/A N/A

Do analysts prefer BDRX or VTGN?

VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 234.74%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has better valuation and earnings, BDRX or VTGN?

Biodexa Pharmaceuticals has higher earnings, but lower revenue than VistaGen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A VistaGen Therapeutics $1.27M 9.92 -$69.68M -$1.83 N/A

Do analysts rate LNAI or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, LNAI or BDRX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Is LNAI or BDRX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Biodexa Pharmaceuticals N/A N/A N/A

Do analysts recommend BDRX or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BDRX or XCUR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A Exicure N/A N/A -$4.95M -$1.55 N/A

Is BDRX or XCUR more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Exicure N/A -179.41% -64.37%

Biodexa Pharmaceuticals (BDRX) Competitors

$1.47 -0.12 (-7.55%)

Closing price 04:00 PM Eastern

Extended Trading

$1.43 -0.04 (-2.79%)

As of 05:01 PM Eastern

Compare

BDRX vs. KTTA, GDTC, VTGN, LNAI, and XCUR

Should you buy Biodexa Pharmaceuticals stock or one of its competitors? MarketBeat compares Biodexa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodexa Pharmaceuticals include Pasithea Therapeutics (KTTA), CytoMed Therapeutics (GDTC), VistaGen Therapeutics (VTGN), Lunai Bioworks (LNAI), and Exicure (XCUR). These companies are all part of the "biotechnology" industry.

How does Biodexa Pharmaceuticals compare to Pasithea Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Biodexa Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Pasithea Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 576.28%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biodexa Pharmaceuticals' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Summary

Pasithea Therapeutics beats Biodexa Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to CytoMed Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
CytoMed Therapeutics	N/A	N/A	N/A

In the previous week, Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
CytoMed Therapeutics	Neutral

CytoMed Therapeutics has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
CytoMed Therapeutics	$250K	42.11	-$3.10M	N/A	N/A

Biodexa Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Summary

Biodexa Pharmaceuticals beats CytoMed Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Biodexa Pharmaceuticals has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. Biodexa Pharmaceuticals' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 234.74%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Biodexa Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

In the previous week, VistaGen Therapeutics had 4 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 4 mentions for VistaGen Therapeutics and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled VistaGen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
VistaGen Therapeutics	Neutral

Biodexa Pharmaceuticals has higher earnings, but lower revenue than VistaGen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
VistaGen Therapeutics	$1.27M	9.92	-$69.68M	-$1.83	N/A

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

VistaGen Therapeutics beats Biodexa Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

In the previous week, Lunai Bioworks had 3 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for Lunai Bioworks and 0 mentions for Biodexa Pharmaceuticals. Lunai Bioworks' average media sentiment score of 0.00 equaled Biodexa Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Biodexa Pharmaceuticals	Neutral

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lunai Bioworks has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

Biodexa Pharmaceuticals' return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

Summary

Biodexa Pharmaceuticals beats Lunai Bioworks on 4 of the 7 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Exicure?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Exicure had 3 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for Exicure and 0 mentions for Biodexa Pharmaceuticals. Exicure's average media sentiment score of 0.67 beat Biodexa Pharmaceuticals' score of 0.00 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Exicure	Positive

Biodexa Pharmaceuticals' return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Exicure	N/A	-179.41%	-64.37%

Biodexa Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, Exicure has a beta of 3.65, indicating that its share price is 265% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A
Exicure	N/A	N/A	-$4.95M	-$1.55	N/A

Summary

Exicure beats Biodexa Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDRX vs. The Competition

Export

Metric	Biodexa Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.93M	$3.61B	$6.93B	$12.84B
Dividend Yield	N/A	3.77%	2.60%	9.78%
P/E Ratio	N/A	7.68	281.16	25.43
Price / Sales	N/A	1,223.93	575.77	80.37
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	0.01	17.03	12.86	6.06
Net Income	-$8.42M	-$12.50M	$3.49B	$348.34M
7 Day Performance	-0.68%	2.90%	2.63%	3.03%
1 Month Performance	-48.78%	-4.49%	-2.64%	-3.04%
1 Year Performance	-95.65%	54.14%	76.00%	20.65%

Biodexa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDRX Biodexa Pharmaceuticals	0.7526 of 5 stars	$1.47 -7.5%	N/A	-95.4%	$2.93M	N/A	N/A	20
KTTA Pasithea Therapeutics	2.8968 of 5 stars	$0.46 +3.0%	$3.00 +552.2%	-35.3%	$11.14M	N/A	N/A	3	News Coverage Upcoming Earnings Gap Down
GDTC CytoMed Therapeutics	0.9426 of 5 stars	$0.85 -7.3%	N/A	-54.2%	$10.88M	$250K	N/A	N/A	Gap Up
VTGN VistaGen Therapeutics	1.7508 of 5 stars	$0.30 +22.4%	$0.95 +216.7%	-89.8%	$10.87M	$1.27M	N/A	40	News Coverage High Trading Volume
LNAI Lunai Bioworks	0.5449 of 5 stars	$2.55 +6.7%	N/A	N/A	$10.84M	N/A	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDRX) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. KTTA, GDTC, VTGN, LNAI, and XCUR

How does Biodexa Pharmaceuticals compare to Pasithea Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to CytoMed Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to Lunai Bioworks?

Summary

How does Biodexa Pharmaceuticals compare to Exicure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. KTTA, GDTC, VTGN, LNAI, and XCUR

How does Biodexa Pharmaceuticals compare to Pasithea Therapeutics?

Which has more risk & volatility, BDRX or KTTA?

Does the media prefer BDRX or KTTA?

Which has higher valuation & earnings, BDRX or KTTA?

Do analysts rate BDRX or KTTA?

Do institutionals and insiders hold more shares of BDRX or KTTA?

Is BDRX or KTTA more profitable?

Summary

How does Biodexa Pharmaceuticals compare to CytoMed Therapeutics?

Do analysts recommend BDRX or GDTC?

Do insiders & institutionals hold more shares of BDRX or GDTC?

Is BDRX or GDTC more profitable?

Does the media prefer BDRX or GDTC?

Which has higher earnings & valuation, BDRX or GDTC?

Which has more risk and volatility, BDRX or GDTC?

Summary

How does Biodexa Pharmaceuticals compare to VistaGen Therapeutics?

Is BDRX or VTGN more profitable?

Do analysts prefer BDRX or VTGN?

Which has more volatility and risk, BDRX or VTGN?

Does the media favor BDRX or VTGN?

Which has better valuation and earnings, BDRX or VTGN?

Do insiders and institutionals hold more shares of BDRX or VTGN?

Summary

How does Biodexa Pharmaceuticals compare to Lunai Bioworks?

Does the media prefer LNAI or BDRX?

Do institutionals and insiders have more ownership in LNAI or BDRX?

Which has more risk & volatility, LNAI or BDRX?

Is LNAI or BDRX more profitable?

Do analysts rate LNAI or BDRX?

Which has stronger earnings & valuation, LNAI or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Exicure?

Do analysts recommend BDRX or XCUR?

Do insiders and institutionals hold more shares of BDRX or XCUR?

Does the media refer more to BDRX or XCUR?

Is BDRX or XCUR more profitable?

Which has more risk & volatility, BDRX or XCUR?

Which has higher valuation and earnings, BDRX or XCUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools